LP
LPCN.US Lipocine Inc
- Market cap
- USD 18.9M
- P/E
- -
- P/B
- 0.89x
- ROE
- -43.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LPCN.US undervalued?
Graham numberThe Graham number of Lipocine Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lipocine Inc fundamental analysis
No fundamental analysis for Lipocine Inc yet.
Lipocine Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Pha…
Full company profileLipocine Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lipocine Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 428K | 165K | 0.04 | 16.1M | 500K | -2.85M | 11.2M | 1.98M | 3.47M |
| Gross Profit | -8.08M | -11.0M | 428K | -7.30M | -9.75M | 8.48M | -8.06M | -13.0M | 11.2M | -6.61M | 3.45M |
| Operating Income | -18.5M | -21.2M | -11.3M | -12.9M | -18.0M | 3.15M | -12.1M | -17.9M | -1.16M | -10.4M | -10.1M |
| EBITDA | -18.9M | -21.2M | -11.3M | -12.2M | -18.0M | -431K | -10.7M | -16.3M | 50.1K | -9.57M | -9.24M |
| Net Income | -19.0M | -21.0M | -11.7M | -13.0M | -21.0M | -634K | -10.8M | -16.4M | 8.35K | -9.63M | -9.28M |
| EPS | -18 | -18 | -9.28 | -8.54 | -6.40 | -0.12 | -2.05 | -3.10 | 0.00 | -1.69 | -1.13 |
| Balance Sheet | |||||||||||
| Total Assets | 27.3M | 25.3M | 20.9M | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 22.5M | 17.0M | 23.2M |
| Total Liabilities | 1.33M | 6.35M | 11.4M | 13.4M | 10.0M | 6.91M | 1.91M | 2.63M | 1.51M | 2.53M | 2.03M |
| Shareholders' Equity | 26.0M | 19.0M | 9.43M | 6.29M | 15.3M | 45.6M | 35.6M | 20.4M | 21.0M | 14.5M | 21.2M |
| Cash & Short-term Investments | 26.8M | 21.5M | 15.3M | 14.1M | 19.7M | 44.6M | 32.5M | 22.0M | 21.6M | 14.9M | 21.5M |
| Total Debt | - | - | 10.3M | 7.15M | 5.59M | 2.31M | - | 17.2K | 439K | 450K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.3M | -16.7M | -12.1M | -11.7M | -15.3M | -4.41M | -12.0M | -11.9M | -1.22M | -9.76M | -9.46M |
| Capital Expenditure | 59.7K | 0.00 | 7.59K | 7.59K | 7.59K | 7.59K | 134K | 13.2K | 90.1K | 1.00 | 4.00 |
| Free Cash Flow | -18.3M | -16.7M | -12.1M | -11.7M | -15.3M | -4.42M | -12.1M | -11.9M | -1.31M | -9.76M | -9.46M |
| Ratios | |||||||||||
| ROE | -72.9% | -110.6% | -123.6% | -206.9% | -136.7% | -1.4% | -30.2% | -80.3% | 0.0% | -66.5% | -43.9% |
| ROA | -69.4% | -82.9% | -55.9% | -66.2% | -82.7% | -1.2% | -28.7% | -71.1% | 0.0% | -56.6% | -40.0% |
| Net Profit Margin | - | - | -2,724.1% | -7,883.7% | -52,412,047,500.0% | -3.9% | -2,151.7% | - | 0.1% | -487.1% | -267.8% |
| Debt to Equity | - | - | 1.09x | 1.14x | 0.36x | 0.05x | - | 0.00x | 0.02x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lipocine Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 211K | 0.04 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:17 on May 12, 2023.
Who owns Lipocine Inc
- Insiders 4.17%
- Institutions 26.31%
- Public & others 69.52%
- Shares outstanding 11.1M
- Free float 8.75M
Top funds holding LPCN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 143K | 1.73% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 43.4K | 0.53% | -0.37% | Sep 2026 |
| Fidelity Total Market Index | 8.69K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 8.29K | 0.10% | 0.00% | Sep 2026 |
| DFA US Sustainability Core 1 | 6.18K | 0.08% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 6.04K | 0.07% | 0.00% | Oct 2026 |
| Dimensional US Sustainability Core 1 ETF | 5.18K | 0.06% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 5.12K | 0.06% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 5.12K | 0.06% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 5.04K | 0.06% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 4.76K | 0.06% | 0.00% | Oct 2026 |
| DFA US Vector Equity Class F | 3.50K | 0.04% | 0.00% | Aug 2026 |
| Schwab Total Stock Market Index | 2.94K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 2.16K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.75K | 0.02% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.69K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding LPCN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Squadron Capital Management LLC | 810K | 9.82% | +80.00% | Jun 2026 |
| Ikarian Capital, LLC | 509K | 6.17% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 295K | 3.58% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 231K | 2.80% | +15.03% | Jun 2026 |
| Acadian Asset Management LLC | 170K | 2.07% | 0.00% | Sep 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 140K | 1.70% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 95.2K | 1.15% | +375.49% | Jun 2026 |
| BlackRock Inc | 89.3K | 1.08% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 84.9K | 1.03% | +151.52% | Jun 2026 |
| Citadel Advisors Llc | 81.2K | 0.99% | +179.23% | Jun 2026 |
| Seven Fleet Capital Management LP | 78.8K | 0.96% | -36.90% | Jun 2026 |
| Geode Capital Management, LLC | 74.5K | 0.90% | +17.96% | Jun 2026 |
| Renaissance Technologies Corp | 70.3K | 0.85% | +1.55% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 54.5K | 0.66% | +68.26% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 38.0K | 0.46% | +3.34% | Sep 2026 |
| HRT FINANCIAL LLC | 29.2K | 0.35% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 25.4K | 0.31% | +1.88% | Jun 2026 |
| State Street Corp | 22.4K | 0.27% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 18.7K | 0.23% | 0.00% | Jun 2026 |
| Birchview Capital, LP | 16.7K | 0.20% | -85.05% | Jun 2026 |
Lipocine Inc company profile
- Company name
- Lipocine Inc
- Ticker
- LPCN.US
- Exchange
- USA Stocks
- Listed since
- Oct 22, 2013
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 14
- Fiscal year end
- December
- Address
- 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
- Phone
- 801 994 7383
- Website
- lipocine.com
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Lipocine Inc management
5- Dr. Mahesh V. Patel Ph.D.Co-Founder, President, CEO & Director · born 1957
- Ms. Krista FogartyPrincipal Accounting Officer & Corporate Controller · born 1968
- Dr. Nachiappan Chidambaram Ph.D.Senior Vice President of Research & Development · born 1969
- Mr. Logan MorseVice President of Sales, Marketing & Operations · born 1970
- Dr. Anthony DelConte M. D., M.D.Chief Medical Director · born 1958